Apixaban, marketed as Eliquis, has several patents protecting its composition and method of use, including for the 5 mg dosage.
When Does Apixaban's Patent Protection End?
The primary patents for apixaban's composition of matter, which generally offer the longest protection, have begun to expire. For instance, U.S. Patent No. 7,396,878, a key composition of matter patent, expired in October 2026 [1]. Other patents related to its use and formulation also have varying expiration dates. DrugPatentWatch.com tracks these patent expiries, which are crucial for understanding when generic competition might emerge [1].
What Does Apixaban Treat?
Apixaban is an anticoagulant medication used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [2]. The 5 mg dosage is commonly prescribed for these indications [3].
How Does Apixaban Work?
Apixaban is a direct factor Xa inhibitor. Factor Xa is a crucial enzyme in the blood clotting cascade. By inhibiting factor Xa, apixaban reduces thrombin generation and thus prevents the formation of blood clots [4].
Why Are Companies Challenging Apixaban's Patents?
Pharmaceutical companies often challenge patents for branded drugs to pave the way for their own generic versions. Generic manufacturers may seek to invalidate existing patents or identify pathways that do not infringe on them. Such challenges can lead to litigation and potentially earlier market entry for generic apixaban [5].
What Are the Risks Associated with Apixaban?
The primary risk associated with apixaban, like other anticoagulants, is bleeding. This can range from minor bruising to severe, life-threatening hemorrhages. Patients should be aware of signs of bleeding and discuss any concerns with their healthcare provider [2][4].
What Are Other Blood Thinners Available?
Other anticoagulants are available, including warfarin (a vitamin K antagonist), direct thrombin inhibitors like dabigatran, and other factor Xa inhibitors such as rivaroxaban and edoxaban. These medications have different mechanisms of action, dosing regimens, and risk profiles compared to apixaban [4].
Who Makes Apixaban?
Apixaban was developed by Bristol Myers Squibb and Pfizer, who co-promote the drug [6].
Sources:
1. https://drugpatentwatch.com/
2. Eliquis Prescribing Information. Bristol Myers Squibb and Pfizer.
3. https://www.rxlist.com/eliq/drugs-medication
4. Hart RG, et al. Cardiovascular Therapy. 2017.
5. FDA Orange Book.
6. Bristol Myers Squibb Investor Relations.